AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8732960 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine 10 mg/d
Number of subjects: 173
Study 8732960 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine 15 mg/d
Number of subjects: 173
Study 8732960 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine 20 mg/d
Number of subjects: 173
Study 8732960 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine 30 mg/d
Number of subjects: 173
Study 8732960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study 1880321 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 15 mg/week
Number of subjects: 10
Study 1880321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7068865 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive imagery group
Number of subjects: 30
Study 7068865 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive imagery group who elaborated on their daydreams
Number of subjects: 30
Study 7068865 — intervention group
Group type: COMPARATOR
Intervention: No treatment control
Number of subjects: 30
Study 31711229 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress group (Trier Social Stress Test)
Number of subjects: 58
Study 31711229 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo TSST)
Number of subjects: 58
Study 31261732 — intervention group
Group type: EXPERIMENTAL
Intervention: ONS-D with isomaltulose and sucromalt
Number of subjects: 16
Study 31261732 — intervention group
Group type: COMPARATOR
Intervention: Standard formula (ET)
Number of subjects: 16
Study 29036790 — intervention group
Group type: EXPERIMENTAL
Intervention: Endostar combined with NP chemotherapy
Number of subjects: 26
Study 29036790 — intervention group
Group type: COMPARATOR
Intervention: NP chemotherapy alone (Control)
Number of subjects: 26
Study 26445179 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee (100 mL 3 times daily)
Number of subjects: 105
Study 26445179 — intervention group
Group type: COMPARATOR
Intervention: Caffeinated coffee (100 mL 3 times daily)
Number of subjects: 105
Study 26445179 — intervention group
Group type: COMPARATOR
Intervention: Water (100 mL 3 times daily)
Number of subjects: 105
Study 24196661 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training
Number of subjects: 34
Study 24196661 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher premorbid intellect, greater occupational attainment, superior memory, and higher levels of functioning
Number of subjects: 34
Study 24196661 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression and disability
Number of subjects: 34
Study 22938928 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician intervention
Number of subjects: 240
Study 22938928 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician+patient intervention
Number of subjects: 240
Study 22938928 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 240
Study 19445546 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 0
Study 19445546 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 0
Study 19445546 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CBT plus sertraline
Number of subjects: 0
Study 19445546 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine 25 mg/day, Fluoxetine 10 mg/day, Sertraline 25 mg/day
Number of subjects: 0
Study 19445546 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy with systematic tracking of treatment-emergent adverse events
Number of subjects: 0
Study 19445546 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term medication use
Number of subjects: 0
Study 17855758 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) at 50% MIP
Number of subjects: 16
Study 17855758 — intervention group
Group type: COMPARATOR
Intervention: Inspiratory muscle training (IMT) at 10% MIP (Control)
Number of subjects: 16
Study 15623680 — intervention group
Group type: EXPERIMENTAL
Intervention: Petasites extract 75 mg bid
Number of subjects: 245
Study 15623680 — intervention group
Group type: EXPERIMENTAL
Intervention: Petasites extract 50 mg bid
Number of subjects: 245
Study 15623680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 245
Study 11336083 — intervention group
Group type: EXPERIMENTAL
Intervention: Delapril 30 mg/day
Number of subjects: 60
Study 11336083 — intervention group
Group type: EXPERIMENTAL
Intervention: Manidipine 10 mg/day
Number of subjects: 60
Study 9203933 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 60 mg/day for three days and 80 mg intravenous before perfusion
Number of subjects: 9
Study 9203933 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 600 mg/day for three days and 50 mg/h intravenous during perfusion
Number of subjects: 9
Study 7969831 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (early surgery < or = 25 hours after injury or late surgery > 200 hours)
Number of subjects: 0
Study 7969831 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 0
Study 3308483 — intervention group
Group type: EXPERIMENTAL
Intervention: Single five-drug combination (adriamycin 50 mg, vincristine 1.5 mg, 5-fluorouracil 750 mg intravenously; methotrexate 50 mg intramuscularly; chlorambucil 10 mg orally, followed by three doses of chlorambucil 10 mg at 6-h intervals)
Number of subjects: 262
Study 3308483 — intervention group
Group type: COMPARATOR
Intervention: Alternating combinations of two three-drug regimens (Regimen A: vincristine 1.5 mg, adriamycin 70 mg, methotrexate 50 mg; Regimen B: 5-fluorouracil 750 mg, vindesine 5 mg intravenously, cyclophosphamide 50 mg orally, followed by three doses of cyclophosphamide 50 mg at 6-h intervals)
Number of subjects: 262
Study 3308483 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups (single and alternating combinations)
Number of subjects: 262
Study 31640628 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation by 5 independent pancreatic surgeons using pretherapeutic CT or MRI scans.
Number of subjects: 200
Study 28657702 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium monofluorophosphate (SMFP) dentifrice containing 1500 ppm F with 5% calcium sodium phosphosilicate (CSPS)
Number of subjects: 77
Study 28657702 — intervention group
Group type: COMPARATOR
Intervention: Sodium monofluorophosphate (SMFP) dentifrice containing 1500 ppm F with 0% CSPS
Number of subjects: 77
Study 26210757 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequence-positive participants
Number of subjects: 182
Study 24450890 — intervention group
Group type: EXPERIMENTAL
Intervention: Solanezumab (400 mg administered intravenously every 4 weeks for 18 months)
Number of subjects: 2052
Study 24450890 — intervention group
Group type: COMPARATOR
Intervention: Solanezumab
Number of subjects: 2052
Study 21104046 — intervention group
Group type: EXPERIMENTAL
Intervention: Minute ventilation (MV) sensor
Number of subjects: 1000
Study 21104046 — intervention group
Group type: COMPARATOR
Intervention: Accelerometer (XL) sensor
Number of subjects: 1000
Study 20426290 — intervention group
Group type: EXPERIMENTAL
Intervention: Polygalactin‐910 continuous suturing (Group A)
Number of subjects: 174
Study 20426290 — intervention group
Group type: EXPERIMENTAL
Intervention: Polygalactin‐910 interrupted suturing (Group B)
Number of subjects: 174
Study 20426290 — intervention group
Group type: COMPARATOR
Intervention: Polypropylene continuous suturing (Group C)
Number of subjects: 174
Study 20426290 — intervention group
Group type: COMPARATOR
Intervention: Polypropylene interrupted suturing (Group D)
Number of subjects: 174
Study 17167126 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible coping psychotherapy (FCP)
Number of subjects: 75
Study 17167126 — intervention group
Group type: COMPARATOR
Intervention: Supportive psychotherapy (SPP)
Number of subjects: 75
Study 15170011 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with single dose (2 g) metronidazole and clotrimazole cream for 3 days, randomized to follow-up strategies
Number of subjects: 726
Study 15170011 — intervention group
Group type: COMPARATOR
Intervention: Follow-up strategy A: Come back on day 7 only if no improvement in discharge
Number of subjects: 726
Study 15170011 — intervention group
Group type: COMPARATOR
Intervention: Follow-up strategy B: Come back on day 7 regardless of response to treatment
Number of subjects: 726
Study 15170011 — intervention group
Group type: COMPARATOR
Intervention: Comprehensive interventions for sex workers in Ghana and Bénin
Number of subjects: 726
Study 12041052 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-suction method
Number of subjects: 20
Study 12041052 — intervention group
Group type: COMPARATOR
Intervention: Closed-suction method
Number of subjects: 20
Study 9660431 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide acetate (3.75 mg every 28 days IM) + placebo tablets (group A)
Number of subjects: 50
Study 9660431 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate (3.75 mg every 28 days IM) + 2.5 mg of tibolone per os (group B)
Number of subjects: 50
Study 9660431 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide acetate + placebo (group A)
Number of subjects: 50
Study 9660431 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate + tibolone (group B)
Number of subjects: 50
Study 7640448 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic portal infusion chemotherapy (PPIC)
Number of subjects: 110
Study 7640448 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PPIC)
Number of subjects: 110
Study 2653300 — intervention group
Group type: EXPERIMENTAL
Intervention: misonidazole
Number of subjects: 89
Study 2653300 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 89
Study 782700 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of BCNU, vinblastine, cyclophosphamide, procarbazine, and prednisone
Number of subjects: 0
Study 782700 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of mechlorethamine, vincristine, prednisone, and procarbazine (MOPP)
Number of subjects: 0
Study 782700 — intervention group
Group type: EXPERIMENTAL
Intervention: BCNU given orally
Number of subjects: 0
Study 782700 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl‐CCNU given orally
Number of subjects: 0
Study 31715173 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized quarterly learning curves
Number of subjects: 132
Study 31715173 — intervention group
Group type: COMPARATOR
Intervention: Standard feedback
Number of subjects: 132
Study 31337570 — intervention group
Group type: COMPARATOR
Intervention: Iliac crest bone graft with HAM coverage (n=5)
Number of subjects: 9
Study 31337570 — intervention group
Group type: EXPERIMENTAL
Intervention: Iliac bone grafts covered with HAM loaded with BFSCs (n=4)
Number of subjects: 9
Study 28058589 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 524
Study 28058589 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 524
Study 26198864 — intervention group
Group type: EXPERIMENTAL
Intervention: General palpation method
Number of subjects: 50
Study 26198864 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-finger technique
Number of subjects: 50
Study 26198864 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck crease method
Number of subjects: 50
Study 24033239 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Stepping Stones Triple P (GSSTP)
Number of subjects: 52
Study 21862829 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid blockade (8 mg of naloxone)
Number of subjects: 179
Study 21862829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study 19696704 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg oral transmucosal fentanyl citrate
Number of subjects: 35
Study 19696704 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 17659254 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat + CBTgsh
Number of subjects: 50
Study 17659254 — intervention group
Group type: COMPARATOR
Intervention: Placebo + CBTgsh
Number of subjects: 50
Study 15254883 — intervention group
Group type: EXPERIMENTAL
Intervention: Early nighttime hypoglycemia
Number of subjects: 0
Study 15254883 — intervention group
Group type: COMPARATOR
Intervention: Morning hypoglycemia
Number of subjects: 0
Study 11488781 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 30
Study 11488781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9766793 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (40 IU kg(‐1)i.v., three times weekly)
Number of subjects: 12
Study 9766793 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (24 subjects)
Number of subjects: 12
Study 8001440 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival triamcinolone acetonide (TA)
Number of subjects: 89
Study 8001440 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TA)
Number of subjects: 89
Study 2490828 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive drug treatment
Number of subjects: 420000
Study 2490828 — intervention group
Group type: COMPARATOR
Intervention: Prolonged difference of about 6 mm Hg in DBP
Number of subjects: 420000
Study 6179 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (80 mg)
Number of subjects: 18
Study 6179 — intervention group
Group type: COMPARATOR
Intervention: Practolol (250 mg)
Number of subjects: 18
Study 6179 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (100 mg)
Number of subjects: 18
Study 6179 — intervention group
Group type: COMPARATOR
Intervention: Tolamolol (100 mg)
Number of subjects: 18
Study 6179 — intervention group
Group type: COMPARATOR
Intervention: Tolamolol (200 mg)
Number of subjects: 18
Study 6179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 31466229 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Intervention (CI) - cognitive stimulation program (CSP) and physical exercise program (PEP), 3 times a week for 12 weeks
Number of subjects: 44
Study 31466229 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control Group)
Number of subjects: 44
Study 28945186 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision-making system
Number of subjects: 56
Study 28945186 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 56
Study 26102617 — intervention group
Group type: EXPERIMENTAL
Intervention: Double ureteral stent placement
Number of subjects: 55
Study 26102617 — intervention group
Group type: COMPARATOR
Intervention: Single ureteral stent placement
Number of subjects: 55
Study 23084124 — intervention group
Group type: EXPERIMENTAL
Intervention: Anwar technique
Number of subjects: 57
Study 23084124 — intervention group
Group type: COMPARATOR
Intervention: Melles technique
Number of subjects: 57
Study 16878679 — intervention group
Group type: EXPERIMENTAL
Intervention: Denzir (DZ) system
Number of subjects: 18
Study 16878679 — intervention group
Group type: COMPARATOR
Intervention: In-Ceram Zirconia (InZ) system
Number of subjects: 18
Study 16878679 — intervention group
Group type: EXPERIMENTAL
Intervention: Both systems
Number of subjects: 18
Study 12932213 — intervention group
Group type: EXPERIMENTAL
Intervention: Assigned subordinates who initially wanted to be dominant
Number of subjects: 138
Study 12932213 — intervention group
Group type: COMPARATOR
Intervention: Assigned high-dominance individuals
Number of subjects: 138
Study 10479194 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.6 g n‐3 PUFA
Number of subjects: 60
Study 10479194 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 g n‐3 PUFA
Number of subjects: 60
Study 10479194 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 60
Study 8626360 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 0
Study 8626360 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 0
Study 8626360 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 0
Study 8626360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1649840 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of estrogen alone
Number of subjects: 63
Study 1649840 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous administration of estrogen
Number of subjects: 63
Study 1649840 — intervention group
Group type: EXPERIMENTAL
Intervention: Utrogestan in combination with oral estrogen
Number of subjects: 63
Study 1649840 — intervention group
Group type: EXPERIMENTAL
Intervention: Utrogestan with percutaneous estrogen
Number of subjects: 63
Study 6359083 — intervention group
Group type: EXPERIMENTAL
Intervention: Propiram fumarate 50 mg
Number of subjects: 120
Study 6359083 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine sulfate 60 mg
Number of subjects: 120
Study 6359083 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 30262155 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with T4 normalization after 5 months (median and percentiles 2.0-10.5 months)
Number of subjects: 32
Study 30262155 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with PAH
Number of subjects: 32
Study 30262155 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without cardiovascular disease after T4 normalization
Number of subjects: 32
Study 27357445 — intervention group
Group type: EXPERIMENTAL
Intervention: FCR (fludarabine and cyclophosphamide with rituximab)
Number of subjects: 817
Study 27357445 — intervention group
Group type: COMPARATOR
Intervention: FC (fludarabine and cyclophosphamide)
Number of subjects: 817
Study 26155932 — intervention group
Group type: EXPERIMENTAL
Intervention: HITSystem intervention at intervention hospitals (n=3)
Number of subjects: 720
Study 26155932 — intervention group
Group type: COMPARATOR
Intervention: Standard care at matched control sites (n=3)
Number of subjects: 720
Study 23450336 — intervention group
Group type: EXPERIMENTAL
Intervention: H‐IVIG
Number of subjects: 35
Study 23450336 — intervention group
Group type: COMPARATOR
Intervention: IV immunoglobulin (control)
Number of subjects: 35
Study 21320840 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized interprofessional team approach to community-based stroke rehabilitation (n=52)
Number of subjects: 101
Study 21320840 — intervention group
Group type: COMPARATOR
Intervention: Usual home care (n=49)
Number of subjects: 101
Study 18996068 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational message (beauty ideals)
Number of subjects: 159
Study 18996068 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational message (marketing strategies)
Number of subjects: 159
Study 18996068 — intervention group
Group type: EXPERIMENTAL
Intervention: Photo exposure (attractive females)
Number of subjects: 159
Study 18996068 — intervention group
Group type: COMPARATOR
Intervention: Photo exposure (household products)
Number of subjects: 159
Study 16683273 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 70
Study 16683273 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 70
Study 14595048 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphtheria-tetanus-acellular pertussis vaccine (DTaP)
Number of subjects: 788
Study 14595048 — intervention group
Group type: COMPARATOR
Intervention: Diphtheria-tetanus vaccine only (DT)
Number of subjects: 788
Study 14595048 — intervention group
Group type: EXPERIMENTAL
Intervention: Culture-positive patients
Number of subjects: 788
Study 14595048 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment
Number of subjects: 788
Study 14595048 — intervention group
Group type: EXPERIMENTAL
Intervention: Girls (after 3 years of age)
Number of subjects: 788
Study 14595048 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 788
Study 10800239 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 14
Study 10800239 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 14
Study 10800239 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 10800239 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil without midazolam
Number of subjects: 14
Study 8804804 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 micrograms oral misoprostol
Number of subjects: 70
Study 8804804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 1615883 — intervention group
Group type: EXPERIMENTAL
Intervention: dF 15 mg twice daily for 26 weeks
Number of subjects: 45
Study 1615883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 6151206 — intervention group
Group type: EXPERIMENTAL
Intervention: Divided dosage (DD) of prazepam 40 mg per day (10 mg in the morning, 10 mg at noon, 20 mg in the evening)
Number of subjects: 20
Study 6151206 — intervention group
Group type: COMPARATOR
Intervention: Single dosage (SD) of prazepam 40 mg per day (40 mg in the evening)
Number of subjects: 20
Study 30654138 — intervention group
Group type: EXPERIMENTAL
Intervention: Cubist (M5 rule‐based model with corrections based on nearest neighbors)
Number of subjects: 83
Study 30654138 — intervention group
Group type: EXPERIMENTAL
Intervention: M5 regression tree
Number of subjects: 83
Study 30654138 — intervention group
Group type: EXPERIMENTAL
Intervention: extremely randomized regression trees (extraTrees)
Number of subjects: 83
Study 30654138 — intervention group
Group type: EXPERIMENTAL
Intervention: least angle regression (lars)
Number of subjects: 83
Study 30654138 — intervention group
Group type: EXPERIMENTAL
Intervention: non‐negative least squares (nnls)
Number of subjects: 83
Study 30654138 — intervention group
Group type: EXPERIMENTAL
Intervention: Committee of neural networks (avNNet)
Number of subjects: 83
Study 30654138 — intervention group
Group type: EXPERIMENTAL
Intervention: random forest (rf)
Number of subjects: 83
Study 30654138 — intervention group
Group type: EXPERIMENTAL
Intervention: ε‐support vector regression (svr)
Number of subjects: 83
Study 29738057 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP block with 30 mL 0.25% levobupivacaine
Number of subjects: 75
Study 29738057 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic infiltration with 20 mL of levobupivacaine 0.5%
Number of subjects: 75
Study 29738057 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TAP block or LAI)
Number of subjects: 75